Intracellular Th (ITCI)

is a clinical stage biopharmaceutical company that focuses on developing therapies for central nervous system (CNS) disorders. One of their main products under development is CAPLYTA (Lumateperone), a potential treatment for bipolar depression and major depressive disorder (MDD). Intra-Cellular is conducting a global clinical trial, Study 403, to evaluate the efficacy and safety of Lumateperone 42 mg in patients with MDD and bipolar depression who exhibit mixed features. The primary endpoint of the study is change from baseline versus placebo on the Montgomery-Asberg Depression Rating scale (MADRS) total score at week 6, and the key secondary endpoint is the Clinical Global Impression (CGI-S) scale. The study is a randomized, double-blind, placebo-controlled, multicenter study. Major Depressive Disorder (MDD) is a common mood disorder that affects an estimated 21 million adults in the United States. It can lead to a range of symptoms, including sadness, hopelessness, cognitive impairment, and suicidal thoughts. Despite being a large unmet medical need, only one-third of treated patients adequately respond to first-line therapy. Bipolar depression is a subtype of depression that occurs in people with bipolar disorder, and mixed features are common in about one-third of patients with MDD and bipolar depression. The topline results from Study 403 are expected to be reported in the first quarter of 2023.

In a $ 31,29, sottovalutato da molti, da molto tempo. Opinioni?

dai, rompili sti 33 e virgola :)

Panico

Occasione d'acquisto irripetibile

No hope for this stock?

Andiamo a più 10 forza

C I siete

ma che bel regalo di Natale

Grazie Intracellular :))

Salve a tutti

Si anch'io dentro, target 18/20 $

prese a 11,02 , qualcuno è dentro?